Skip to main content

Valerian

Scientific Name(s): Centranthus ruber L., Valeriana edulis, Valeriana officinalis L., Valeriana sambucifolia Mik., Valeriana wallichi DC.
Common Name(s): Baldrian, Cat's love, Cat's valerian, Garden heliotrope, Garden valerian, Kesso root, Radix valerianae, St. George's herb, Valerian, Valerian fragrant, Vandal root

Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.

Clinical Overview

Use

The evidence to support the common use of valerian in insomnia remains weak. However, as valerian preparations seem to have a wide margin of safety, further trials for insomnia and anxiety may be warranted. Very limited data have been published concerning use for dysmenorrhea and obsessive-compulsive disorder.

Dosing

Insomnia: Valerian extract 400 to 600 mg/day taken 1 hour before bedtime for 2 to 4 weeks has been used in clinical trials.

Contraindications

Contraindications have not been identified.

Pregnancy/Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

Interactions

None well documented.

Adverse Reactions

In general, clinical studies have found valerian to have a wide margin of safety, be devoid of adverse effects, and have fewer adverse reactions than positive control drugs, such as diazepam. Headache and diarrhea have been reported in clinical trials, but hangover is seldom reported. Several cases of hepatotoxicity have been reported.

Toxicology

Valerian has been classified as GRAS (generally recognized as safe) in the United States for food use; extracts and the root oil are used as flavorings in foods and beverages. The observed in vitro cytotoxicity of valepotriate compounds may not be relevant in vivo because of limited absorption.

Scientific Family

Botany

Members of the genus Valeriana are herbaceous perennials widely distributed in the temperate regions of North America, Europe, and Asia. The hollow stemmed plant can grow up to 2 m and is branched at the terminal end with opposite leaves and small white or pink flowers. Fruits are oblong, 4-ridged, and single seeded. Of approximately 200 known species, the Eurasian Vakeruaba officinalis is most often cultivated for medicinal use. The dried rhizome used in valerian extracts has numerous rootlets and one or more stolons and contains a volatile oil with a distinctive, unpleasant odor.1, 2, 3, 4

History

Valerian has been used in Unani, Ayurvedic, and traditional Chinese health systems and for homeopathic uses for cardiotonic and sedative properties, as well as in epilepsy, hysteria, and other conditions.5 Despite its odor, valerian was considered a perfume in 16th-century Europe. The tincture has been used for its sedative properties for centuries; it is still widely used in France, Germany, and Switzerland as a sleep aid.6 Other uses attributed to valerian include a digestive aid, emmenagogue, and antiperspirant.2

Chemistry

Three distinct classes of compounds have been associated with the sedative properties of valerian. These compounds consist of mono- and sesquiterpenes and iridoid triesters (valepotriates). Other compounds identified include flavonoids, triterpenes, lignans, and alkaloids. The composition of the volatile oil varies markedly between cultivars and species, as does the amount and relative proportion of cytotoxic valepotriates, making chemical standardization difficult but highly desirable.

The most important sesquiterpenes include valerenic acid and its congeners, although in Japan, V. officinalis var. latifolia, kessyl alcohols, and esters predominate. Valtrate, acevaltrate, and didrovaltrate are the most important iridoids; European valerian extracts were formerly standardized on these unstable compounds, which have a short shelf life in the tincture.

The alkaloid concentration in roots and rhizomes is low, usually less than 0.2%. The aqueous extract of valerian contains substantial quantities of gamma-aminobutyric acid (GABA); however, it is doubtful whether GABA penetrates the blood-brain barrier.

Many analytical high performance liquid chromatographic methods have been developed for the sesquiterpenes and valepotriates. The seasonal variation in valerenic acids and valepotriates has been studied. Tissue culture of valerian species has focused on the production of valepotriates.2, 7, 8, 9, 10, 11, 12

Uses and Pharmacology

Several in vitro and animal experiments have attempted to elucidate the mechanism of action for various valerian compounds. Many of these experiments provide contradictory evidence, but most attribute the observed actions of valerian extracts to central actions on GABA, serotonin, and adenosine receptors. The sesquiterpene valerenic acid and its derivatives and the valepotriates are generally thought to be the active constituents; however, wide variations in the composition of commercial preparations make interpretation of clinical data difficult.(9, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

Anxiolytic effect

Animal data

Another review of clinical trials and in vitro experiments suggests the effect of valerian may be because of anxiolytic action, rather than sedation.(13) This was demonstrated by a laboratory experiment with rodents that found no decrease in spontaneous locomotor activity and no increase in ether-induced anesthesia, but did find a reduction in anxiety using the elevated plus maize test.(25) Older experiments in rodents found conflicting results for spontaneous motor activity.(22, 26)

Clinical data

Both a meta-analysis and systematic review comment on the lack of trials meeting inclusion criteria because of poor methodology, the use of healthy volunteers, and combination therapies.(14, 23) One small, pilot clinical trial meeting inclusion criteria evaluated the effect of valepotriates 150 mg per day in 3 divided doses over 4 weeks in generalized anxiety disorder. No difference was demonstrated for the standardized valerian extract versus placebo or diazepam 20 mg.(24) Until studies with a larger sample size are conducted, the efficacy of valerian remains unclear.(14, 23) In a 2020 systematic review, overall results regarding the effect of valerian for anxiety were positive. Low- and moderate-quality studies, respectively, reported improvements in stress reactivity in healthy subjects (600 mg/day × 1 week standardized extract) and lower anxiety in HIV-positive patients receiving efavirenz (530 mg/day × 4 weeks valerian root/rhizome). Whereas, 3 high-quality trials reported improvements in anxiety prior to dental surgery (100 mg root/rhizome single dose valerian extract 60 minutes preop), prior to menstruation (1,260 mg/day × 7 days for 3 cycles), and in volunteers with non-clinical anxiety and insomnia (6.4 mg, valerenic acid 1% valerian extract × 28 days). In the meta-analysis, pooled data from 7 randomized controlled trials (N=535) with very high heterogeneity, publication bias, and missing negative outcome data showed no statistically significant difference in the anxiolytic effect of valerian compared to controls. Extracts produced more variation in outcomes than did whole root interventions. However, both single-dose and repeat administration of V. officinalis extracts were shown to improve anxiety-associated brain activity.(59)

Dysmenorrhea

Clinical data

One randomized, controlled clinical trial evaluated the use of valerian compared with identical placebo in college-age women for management of dysmenorrhea symptoms. Both valerian and placebo produced significant reductions in pain compared with baseline scores, but the pain reduction seen with valerian was significantly larger compared with placebo. Severity of systemic symptoms was reduced with both valerian and placebo, with valerian’s scores nonsignificantly lower than placebo scores for all symptoms except syncope. Valerian’s reduction of syncope was significantly lower compared with placebo.(57) In another study, premenstrual symptoms were reduced with administration of valerian extract 1,260 mg/day for 7 days given for 3 cycles.(59)

A Cochrane systematic review and meta-analysis of dietary supplements for dysmenorrhea identified only low or very low quality studies with very small sample sizes. Very limited evidence of effectiveness was found for the treatment of primary dysmenorrhea with valerian 255 mg root powder 3 times daily compared to placebo or no treatment (1 randomized clinical trial, n = 100); however, no difference was identified between valerian 250 mg compared to mefenamic acid 250 mg (1 randomized clinical trial, n = 99).(61)

Insomnia and sleep problems

Clinical data

Single-dose studies have consistently found no effect for a single dose of valerian in improving sleep latency or quality.(27, 28, 29)

A meta-analysis of studies published through September, 2008 evaluated data from eighteen randomized controlled trials (>1300 patients). The authors did not find significant benefits for sleep latency time or sleep quality as rated by visual analogue scale. Patients’ subjective rating of sleep quality did significantly favor valerian.(30) Reviews of older trials not included in the meta-analysis found valerian to exert an effect similar to the benzodiazepines, but a number of negative trials are also described.(5, 13) In a 2020 systematic review of 23 studies, overall results regarding the effect of V. officinalis for sleep problems were equivocal. The most consistent, although not necessarily statistically significant, results were seen when sleep studies were categorized based on product type and duration of intervention in which repeat administration of the dried root or rhizome given for 4 or 8 weeks consistently showed improvement in at least 1 sleep subgroup (5 studies; N=435); however, study populations were highly diverse (eg, HIV-positive, postmenopausal, cancer, Hispanic mental health, restless leg syndrome). Data also consistently showed no significant effect on sleep outcomes for the hydroalcoholic extracts given as a single dose. Results were equivocal for aqueous extracts given as a single dose or repeated over 7 days for the hydroalcoholic extracts given in repeated doses for 2 to 6 weeks and for extracts with unspecified extraction methods. In the meta-analysis, pooled data from 10 randomized controlled trials (N=1,065) with high heterogeneity showed no statistically significant difference with V. officinalis on sleep quality compared to controls.(59)

Two additional studies, one in oncology patients, and the other in postmenopausal females, were published in 2011. The study in cancer patients was a phase III trial that found no significant benefit for insomnia, but valerian did provide statistically significant improvements for the patient-rated, secondary outcomes of fatigue and mood.(31) The study in postmenopausal women found a significant improvement in patient-rated sleep quality with valerian compared with placebo.(32)

Various sleep parameters have also been shown to improve with administration of other valerian species, including V. edulis and V. wallichii. These 2 species lack the valerenic acids that are specific to V. officinalis, but do share the valepotriate constituents. Two high-quality studies that used V. edulis noted improvements in sleep latency and sleep quality in children with intellectual deficit (20 mg/kg × 2 weeks) and improved REM sleep with reduced waking in insomnia patients (450 mg single dose hydroalcoholic extract). A moderate-quality study conducted in insomnia patients reported improved sleep quality with administration of V. wallichii valepotriates (300 mg/day x 15 days).(59)

The American Academy of Sleep Medicine clinical practice guideline for the pharmacologic treatment for chronic insomnia (2017) suggests that valerian not be used as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. Benefits are considered to be approximately equal to risks (Weak; Low).(54) The Veteran’s Administration and Department of Defense (VA/DoD) clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea (2019) suggest against the use of valerian for the treatment of chronic insomnia disorder (Weak).(155)

Menopause

Clinical data

In a triple-blind, randomized, placebo-controlled study that enrolled 60 postmenopausal Iranian women, administration of valerian 530 mg twice daily for 2 months significantly reduced severity (50% none, 40% mild; P=0.02) and frequency (mean diff, −3/day; P=0.03) of hot flushes compared to placebo (0% none, 30% mild and +0.26/day, respectively). Valerian was well tolerated an no side effects were reported.(63) Similar results were observed in another study with valerian extract 1,060 mg/day given for 8 weeks.(59)

Obsessive-compulsive disorder

Clinical data

A randomized, double-blind, placebo-controlled pilot study evaluated valerian in a small group of patients who qualified for inclusion according to DSM-IV-TR criteria for obsessive-compulsive disorder, and Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores 21 or higher. The valerian group had significantly lower Y-BOCS scores beginning 4 weeks after study initiation, and this significant difference continued through the end of study at week 8. Somnolence was reported more frequently in the valerian group.(58)

Postoperative cognitive dysfunction

Clinical data

Cognitive dysfunction has become a common complication after cardiac surgery since the introduction of cardiopulmonary bypass (CPB) in the 1950s and leads to increased length of hospital stay, costs, risk of dementia, and mortality. Mechanisms involved include acute inflammation and decreased serotonin levels. A double-blind, randomized, placebo-controlled trial enrolled 61 adult Iranians who were candidates for coronary artery bypass surgery using CPB to evaluate the effect of V. officinalis (530 mg root extract every 12 hours × 8 weeks) on the prevention of postoperative cognitive dysfunction. Cognitive function was assessed using the Mini-Mental State Examination at baseline, 10 days postoperation, and 60 days postoperation. Patients receiving valerian had reduced odds of cognitive dysfunction compared to placebo based on a generalized estimation equation (estimate, −2.2; odds ratio, 0.108; 95% confidence interval, 0.022 to 0.545).(60)

Restless legs syndrome

Clinical data

Guidelines have been published regarding the use of valerian in restless legs syndrome (RLS). A joint European task force developed evidence-based guidelines on the management of RLS (2012) and stated that a low quality study with valerian failed to demonstrate efficacy in the treatment of RLS symptoms or sleep.(55) Likewise, an American Academy of Sleep Medicine evidence-based guideline (2012) determined there is insufficient evidence at present to evaluate the use of valerian for RLS based on one small controlled trial.(56)

Other uses

The valepotriates, isovaltrate, and valtrate, along with valerenone, had antispasmodic effects in isolated guinea pig ileum and other smooth muscle preparations.(33)

Valerian had no effect on haloperidol-induced orofacial dyskinesia in rats.(34)

Oral administration of valerian root extracts was protective against vasopressin-induced coronary spasms and pressor response in guinea pigs.(7) In the same experiment, bronchial resistance was reduced in both histamine- and antigen-induced bronchospasm.(7)

In a low-quality trial, cognition in hemodialysis patients was reported to improve with 530 mg/day of valerian root/rhizome given for 1 month.(59)

Dosing

A dose of a commercial preparations of valerian extract 600 mg in healthy subjects peaked at 30 minutes to 2 hours, with an elimination half-life of 1.1 ± 0.6 hours, and the marker valerenic acid was in the serum for at least 5 hours after dosing.(35)

Insomnia

Valerian extract 400 to 600 mg taken 1 hour before bedtime for 2 to 4 weeks has been used in clinical trials evaluating valerian in insomnia.(32)

Pregnancy / Lactation

Despite common use without apparent harm during pregnancy, the use of valerian preparations in pregnancy and lactation cannot be supported without evidence of safety. Widespread differences in dosages, duration, and preparations exist, and the stage of pregnancy may be a factor.37 Valerian is reported in the Complete German Commission E Monographs to stimulate uterine contractions.38 Information regarding safety and efficacy in pregnancy and lactation is lacking.

Interactions

Alcohol (ethyl): CNS depressants may enhance the CNS depressant effect of alcohol (ethyl). Monitor therapy.(65)

Azelastine (nasal): CNS depressants may enhance the CNS depressant effect of azelastine (nasal). Avoid combination.(66, 67, 68)

Benzodiazepines: Valerian may enhance the adverse/toxic effect of benzodiazepines. Monitor therapy.(48, 49, 50, 51, 52, 53)

Blonanserin: CNS depressants may enhance the CNS depressant effect of blonanserin. Consider therapy modification.(69)

Brimonidine (topical): Brimonidine (topical) may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(70, 71, 72, 73, 74)

Bromopride: Bromopride may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(75)

Bromperidol: Bromperidol may enhance the CNS depressant effect of CNS depressants. Avoid combination.(76)

Buprenorphine: Depressants may enhance the CNS depressant effect of buprenorphine.(77, 78, 79, 80, 81)

Cannabis: Cannabis may enhance the CNS depressant effect of CNS depressants. Monitor therapy. This interaction is only expected when physiologically significant amounts of tetrahydrocannabinol (THC, the major known psychoactive component of cannabis) are introduced systemically. While this encompasses the vast majority of medical and recreational cannabis use, some cannabis strains, products, and routes of administration specifically (and often intentionally) minimize systemic THC exposure.(82, 83, 84, 85, 86, 87, 88, 89)

Chlormethiazole: Chlormethiazole may enhance the CNS depressant effect of CNS depressants. Consider therapy modification.(90)

Chlorphenesin carbamate: Chlorphenesin carbamate may enhance the adverse/toxic effect of CNS depressants. Monitor therapy.(153)

CNS depressants: Valerian may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(28, 29, 43, 48, 49, 51, 157, 158, 159, 160, 161)

Dimethindene (topical): Dimethindene (topical) may enhance the CNS depressant effect of CNS depressants. Monitor therapy. This interaction is mentioned only in dimethindene nasal product labeling. It is not mentioned in dimethindene topical gel product information.(154)

Doxylamine: Doxylamine may enhance the CNS depressant effect of CNS Depressants. Monitor therapy. Use of Diclegis (doxylamine/pyridoxine) with other CNS depressants is not recommended and should be avoided.(91)

Dronabinol: Dronabinol may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(83, 84, 86, 87, 88, 93, 94)

Droperidol: Droperidol may enhance the CNS depressant effect of CNS depressants. Consider therapy modification.(95)

Flunitrazepam: CNS depressants may enhance the CNS depressant effect of flunitrazepam. Consider therapy modification.(96, 97)

Hydrocodone: CNS depressants may enhance the CNS depressant effect of hydrocodone. Consider therapy modification.(98, 99, 100, 101, 102, 103)

Hydroxyzine: Hydroxyzine may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(104)

Kava kava: Kava kava may enhance the adverse/toxic effect of CNS depressants. Monitor therapy.(105, 106, 107, 108, 109)

Lofexidine: Lofexidine may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(110, 111)

Magnesium sulfate: Magnesium sulfate may enhance the CNS depressant effect of CNS depressants. Monitor therapy. The significance of this interaction is likely considerably greater with higher magnesium sulfate doses. Similarly, the use of injectable magnesium sulfate appears to increase the significance of this potential interaction.(112, 113, 114, 115, 116, 117, 118)

Methotrimeprazine: CNS depressants may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS depressants. Consider therapy modification.(119)

Metyrosine: CNS depressants may enhance the sedative effect of metyrosine. Monitor therapy.(120)

Minocycline: Minocycline may enhance the CNS depressant effect of CNS depressants. Monitor therapy. This interaction only applies to the intravenous administration of minocycline.(112, 113, 114, 115, 116, 117, 118, 121)

Mirtazapine: CNS depressants may enhance the CNS depressant effect of mirtazapine. Monitor therapy.(122)

Nabilone: Nabilone may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(123)

Opioid analgesics: CNS depressants may enhance the CNS depressant effect of opioid analgesics. Consider therapy modification.(80, 81, 103, 104, 105, 106, 107, 124)

Orphenadrine: CNS depressants may enhance the CNS depressant effect of orphenadrine. Avoid combination.(125)

Oxomemazine: Oxomemazine may enhance the CNS depressant effect of CNS depressants. Avoid combination.(126)

Oxycodone: CNS depressants may enhance the CNS depressant effect of oxycodone. Consider therapy modification.(81, 98, 99, 100, 101, 102, 127, 128, 129)

Paraldehyde: CNS depressants may enhance the CNS depressant effect of paraldehyde. Avoid combination.(130)

Perampanel: Perampanel may enhance the CNS depressant effect of CNS depressants. Consider therapy modification.(131)

Piribedil: CNS depressants may enhance the CNS depressant effect of piribedil. Monitor therapy.(132)

Pramipexole: CNS depressants may enhance the sedative effect of pramipexole. Monitor therapy.(133)

Ropinirole: CNS depressants may enhance the sedative effect of ropinirole. Monitor therapy.(134)

Rotigotine: CNS depressants may enhance the sedative effect of rotigotine. Monitor therapy.(135)

Rufinamide: Rufinamide may enhance the adverse/toxic effect of CNS depressants. Specifically, sleepiness and dizziness may be enhanced. Monitor therapy.(136)

Selective serotonin reuptake inhibitors: CNS depressants may enhance the adverse/toxic effect of selective serotonin reuptake inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Monitor therapy.(137, 138, 139, 140, 141, 142, 143)

Sodium oxybate: Sodium oxybate may enhance the CNS depressant effect of CNS depressants. Consider therapy modification.(144)

Suvorexant: CNS depressants may enhance the CNS depressant effect of suvorexant. Consider therapy modification.(145)

Tapentadol: Tapentadol may enhance the CNS depressant effect of CNS depressants. Consider therapy modification.(98, 99, 100, 101, 102, 146)

Tetrahydrocannabinol: Tetrahydrocannabinol may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(83, 84, 85, 86, 87, 147)

Thalidomide: CNS depressants may enhance the CNS depressant effect of thalidomide. Avoid combination.(148)

Thiopental: Valerian may enhance the CNS depressant effect of thiopental.(19, 64)

Trimeprazine: Trimeprazine may enhance the CNS depressant effect of CNS depressants. Monitor therapy.(149)

Zolpidem: CNS depressants may enhance the CNS depressant effect of zolpidem. Consider therapy modification. A dose reduction is recommended for Intermezzo brand sublingual zolpidem (applies to men only) but is not applicable to the other zolpidem products.(150, 151, 152)

Valerian drug interactions (more detail)

Adverse Reactions

Valerian has been classified as GRAS in the United States for food use; extracts and the root oil are used as flavorings in foods and beverages.(13)

Generally, clinical studies have found that valerian has a wide margin of safety, is devoid of adverse effects, and has fewer adverse reactions than positive control drugs, such as diazepam. Headache and diarrhea have been reported in clinical trials, but hangover is seldom reported.(5, 6, 13, 24, 30, 31, 32)

An intentional overdose has been reported, in which 20 times the recommended dose was ingested; the patient experienced mild symptoms that resolved within 24 hours.(42) A case of withdrawal after chronic use of valerian has been reported; however, the complex nature of the patient's medical history provides weak evidence of valerian's role.(43) Valerian withdrawal was suspected as the etiology of acute delirium in an elderly male with multiple risk factors for developing delirium (eg, mild neurocognitive disorder, older age, history of mood disorders).(156) Farmers growing valerian were evaluated for adverse reactions, with few notable effects observed.(44)

Hepatotoxicity associated with valerian use was first reported in 1989. Six cases have been reported in women, all of whom reported marked improvement or normalization of liver function tests over 1 to 19 months after valerian discontinuation. However, one case of severe acute hepatitis refractory to improvement subsequent to valerian discontinuation was reported in a 57-year-old man. He had taken 2 g/day of valerian for 3 days and developed worsening liver function over the following 4 weeks. He was successfully treated with oral prednisolone 50 mg daily.(62)

Valerian side effects (more detail)

Toxicology

Concern was raised following the discovery that valepotriates are mutagenic in the Ames assay; however, their poor bioavailability and hepatic detoxification makes them a dubious source of toxicity for patients.2, 45 The cytotoxicity of baldrinal compounds (metabolites of the valepotriates) is higher in vivo than in vitro because they are more readily absorbed, and these metabolites have been detected in commercial preparations.2

No teratogenicity or overt toxicity of valepotriate compounds was found in rodents in 2 different studies.2, 13, 46 Mice receiving doses of valerian more than 1 g/kg by oral and intraperitoneal routes have experienced ataxia, muscle relaxation, and hypothermia.47

No evidence of hepatitis was observed following consumption of oral valerian at average dosages of 2.5 g/day for 4 years.46

Index Terms

References

Disclaimer

This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

Frequently asked questions

1. Valerian. USDA, NRCS. 2009. The PLANTS Database (http://plants.usda.gov, 13 August 2009). National Plant Data Center, Baton Rouge, LA 70874-4490 USA.
2. Valerian. In: WHO monographs on selected medicinal plants. Vol 1. Geneva, Switzerland: World Health Organization; 1999:267-276.
3. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982;17(1):65-71.7122669
4. Houghton PJ. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol. 1999;51(5):505-512.10411208
5. Kumar V. Potential medicinal plants for CNS disorders: an overview. Phytother Res. 2006;20(12):1023-1035.16909441
6. Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119(12):1005-1012.17145239
7. Circosta C, De Pasquale R, Samperi S, Pino A, Occhiuto F. Biological and analytical characterization of two extracts from Valeriana officinalis. J Ethnopharmacol. 2007;112(2):361-367.17467210
8. Gao XQ, Björk L. Valerenic acid derivatives and valepotriates among individuals, varieties and species of Valeriana. Fitoterapia. 2000;71(1):19-24.11449465
9. Santos MS, Ferreira F, Faro C, et al. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H]GABA release in synaptosomes. Planta Med. 1994;60(5):475-476.7997482
10. Bos R, Woerdenbag HJ, Hendriks H, et al. Analytical aspects of phytotherapeutic valerian preparations. Phytochem Anal. 1996;7(3):143-151.
11. Bos R, Woerdenbag HJ, van Putten FM, Hendriks H, Scheffer JJ. Seasonal variation of the essential oil, valerenic acid and derivatives, and valepotriates in Valeriana officinalis roots and rhizomes, and the selection of plants suitable for phytomedicines. Planta Med. 1998;64(2):143-147.9556440
12. Gränicher F, Christen P, Vuagnat P. Rapid high performance liquid chromatographic quantification of valepotriates in hairy root cultures of Valeriana officinalis L. var. sambucifolia Mikan. Phytochem Anal. 1994;5(6):297-301.
13. Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther. 2004;3(2):128-148.15165499
14. Miyasaka LS, Atallah AN, Soares B. Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD004515.17054208
15. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res Mol Brain Res. 2005;138(2):191-197.15921820
16. Ortiz JG, Rassi N, Maldonado PM, González-Cabrera S, Ramos I. Commercial valerian interactions with [3H]flunitrazepam and [3H]MK-801 binding to rat synaptic membranes. Phytother Res. 2006;20(9):794-798.16819753
17. Sichardt K, Vissiennon Z, Koetter U, Brattström A, Nieber K. Modulation of postsynaptic potentials in rat cortical neurons by valerian extracts macerated with different alcohols: involvement of adenosine A1- and GABAA-receptors. Phytother Res. 2007;21(10):932-937.17582590
18. Hiller K-O, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L: behavioural and anticonvulsant properties. Phytother Res. 1996;10(2):145-151.
19. Leuschner J, Müller J, Rudmann M. Characterization of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung. 1993;43(6):638-641.8352816
20. Krieglstein JG, Frusia D. Central depressant constituents in Valeriana. Valepotriate, valerenic acid, valeranone and volatile oil are ineffective afterall. Dtsch Apoth Ztg. 1988;128:2041.
21. Riedel E, Hänsel R, Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives [in German]. Planta Med. 1982;46(4):219-220.7163416
22. Hendriks H, Bos R, Woerdenbag HJ, Koster AS. Central nervous depressant activity of valerenic acid in the mouse. Planta Med. 1985;51(1):28-31.17340394
23. Ernst E. Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine. 2006;13(3):205-208.16428031
24. Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. 2002;16(7):650-654.12410546
25. Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine. 2008;15(1-2):2-15.18160026
26. Hendriks H, Bos R, Allersma DP, Malingré TM, Koster AS. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Med. 1981;42(1):62-68.7255569
27. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000;33(2):47-53.10761819
28. Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res. 2004;18(10):831-836.15551388
29. Hallam KT, Olver JS, McGrath C, Norman TR. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. Hum Psychopharmacol. 2003;18(8):619-625.14696021
30. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo G. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505-511.2034738910.1016/j.sleep.2009.12.009
31. Atherton PJ, Bauer BA, Moore DF Jr, et al.The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). Barton DL, J Support Oncol. 2011;9(1):24-31.10.1016/j.suponc.2010.12.008
32. Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause. 2011;18(9):951-955.2177591010.1097/gme.0b013e31820e9acf
33. Hazelhoff B, Malingré TM, Meijer DK. Antispasmodic effects of Valeriana compounds: an in-vivo and in-vitro study on the guinea-pig ileum. Arch Int Pharmacodyn Ther. 1982;257(2):274-287.7114974
34. Fachinetto R, Villarinho JG, Wagner C, et al. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1478-1486.17669571
35. Anderson GD, Elmer GW, Kantor ED, Templeton IE, Vitiello MV. Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytother Res. 2005;19(9):801-803.16220575
36. Hrastinger A, Dietz B, Bauer R, Sagraves R, Mahady G. Is there clinical evidence supporting the use of botanical dietary supplements in children? J Pediatr. 2005;146(3):311-317.15756210
37. Holst L, Nordeng H, Haavik S. Use of herbal drugs during early pregnancy in relation to maternal characteristics and pregnancy outcome. Pharmacoepidemiol Drug Saf. 2008;17(2):151-159.17992658
38. Ernst E. Herbal medicinal products during pregnancy: are they safe? BJOG. 2002;109(3):227-235.11950176
39. Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. 2008;102(5):466-475.18331390
40. Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther. 2009;8(1):29-36.19174505
41. Chaplin RL Jr, Jedynak J, Johnson D, Heiter D, Shovelton L, Garrett N. The effects of valerian on the time course of emergence from general anesthesia in Sprague-Dawley rats (Rattus norvegicus). AANA J. 2007;75(6):431-435.18179003
42. Willey LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: a case report. Vet Hum Toxicol. 1995;37(4):364-365.8540231
43. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA. 1998;280(18):1566-1567.9820254
44. Skórska C, Golec M, Mackiewicz B, Góra A, Dutkiewicz J. Health effects of exposure to herb dust in valerian growing farmers. Ann Agric Environ Med. 2005;12(2):247-252.16457481
45. von der Hude W, Scheutwinkel-Reich M, Braun R. Bacterial mutagenicity of the tranquilizing constituents of Valerianaceae roots. Mutat Res. 1986;169(1-2):23-27.3511364
46. Yao M, Ritchie HE, Brown-Woodman PD. A developmental toxicity-screening test of valerian. J Ethnopharmacol. 2007;113(2):204-209.17611059
47. Hobbs C. Valerian: a literature review. HerbalGram. 1989;21(1-2):19-34.
48. Carrasco MC, Vallejo JR, Pardo-de-Santayana M, et al. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res. 2009;23(12):1795-1796.19441067
49. Khom S, Baburin I, Timin E, et al. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology. 2007;53(1):178-187.17585957
50. Appel K, Rose T, Fiebich B, et al. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res. 2011;25(6):838-843.21089181
51. Gutierrez S, Ang-Lee MK, Walker DJ, et al. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol Biochem Behav. 2004;78(1):57-64.15159134
52. Ugalde M, Reza V, Gonzalez-Trujano ME, et al. Isobolographic analysis of the sedative interaction between six central nervous system depressant drugs and Valeriana edulis hydroalcoholic extract in mice. J Pharm Pharmacol. 2005;57(5):631-639.15901352
53. Hattesohl M, Feistel B, Sievers H, et al. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine. 2008;15(1-2):2-15.18160026
54. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349.27998379
55. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19(11):1385-1396.22937989
56. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039-1062.22851801
57. Mirabi P, Dolatian M, Mojab F, Majd HA. Effects of valerian on the severity and systemic manifestations of dysmenorrhea. Int J Gynaecol Obstet. 2011;115(3):285-288.2195906810.1016/j.ijgo.2011.06.022
58. Pakseresht S, Boostani H, Sayyah M. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med. 2011 Oct 11;8. pii: /j/jcim.2011.8.issue-1/1553-3840.1465/1553-3840.1465.xml.2271867110.2202/1553-3840.1465
59. Shinjyo N, Waddell G, Green J. Valerian root in treating sleep problems and associated disorders-A systematic review and meta-analysis. J Evid Based Integr Med. 2020;25:2515690X20967323.33086877
60. Hassani S, Alipour A, Khezri HD, et al. Can Valeriana officinalis root extract prevent early postoperative cognitive dysfunction after CABG surgery? A randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2015;232(5):843-850.
61. Pattanittum P, Kunyanone N, Brown J, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016;3: CD002124.27000311
62. Kia YH, Alexander S, Dowling D, Standish R. A case of steroid-responsive alerian-associated hepatitis. Intern Med J. 2016;46(1):118-119.26813905
63. Jenabi E, Shobeiri F, Hazavehei SM, Roshanaei G. The effect of valerian on the severity and frequency of hot flashes: a triple-blind randomized clinical trial. Women Health. 2018;58(3):297-304.28278010
64. Thiopental [summary of product characteristics]. Reading, Berkshire, United Kingdom: Archimedes Pharma UK Limited; January 2014.
65. Worthley LI. Clinical toxicology: Part I. Diagnosis and management of common drug overdosage. Crit Care Resusc. 2002;4(3):192-215.16573429
66. Dymista (azelastine/fluticasone) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc.; April 2012.
67. Astelin (azelastine) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc.; January 2012.
68. Astepro (azelastine) [prescribing information].. Somerset, NJ: Meda Pharmaceuticals Inc.; August 2009.
69. Lonasen (blonanserin) [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200906540. Accessed September 22, 2014.
70. Mirvaso (brimonidine) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P., August 2013.
71. Mungan NK, Wilson TW, Nischal KK, et al. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. J AAPOS. 2003;7(1):69-70.12690374
72. Rangan C, Everson G, Cantrell FL. Central alpha-2 adrenergic eye drops: Case series of 3 pediatric systemic poisonings. Pediatr Emerg Care. 2008;24(3):167-169.18347496
73. Berlin RJ, Lee UT, Samples JR, et al. Ophthalmic drops causing coma in an infant. J Pediatr. 2001;138(3):441-443.11241061
74. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001;5(5):281-284.11641636
75. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.
76. Brom (bromperidol) [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198800802. Accessed October 27, 2017.
77. Suboxone (buprenorphine/naloxone) [prescribing information]. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc; December 2011.
78. Butrans (buprenorphine) [prescribing information]. Stamford, CT: Purdue Pharma LP; June 2014.
79. US Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004. Accessed Online July 8, 2014 at https://www.ncbi.nlm.nih.gov/books/NBK64245/.22514846
80. Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64.28315808
81. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Available from https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.
82. Reisfield GM. Medical cannabis and chronic opioid therapy. J Pain Palliat Care Pharmacother. 2010;24(4):356-361.21133743
83. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prev. 2010;42(6):1855-1865.20728636
84. Siemens AJ. Effects of cannabis in combination with ethanol and other drugs. NIDA Res Monogr. 1980;31:167-198.6106899
85. Hollister LE. Interactions of cannabis with other drugs in man. NIDA Res Monogr. 1986;68:110-116.3095648
86. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology (Berl). 1994;115(3):340-349.7871074
87. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. Anesthesiology. 1975;42(6):674-684.48348
88. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. Alcohol Clin Exp Res. 1988;12(2):268-276.2837105
89. Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. Psychopharmacology (Berl). 1979;66(1):45-50.120541
90. Heminevrin (clomethiazole) [UK summary of product characteristics]. Mesekenhagen, Germany: Cheplapharm Arzneimettel GmbH; April 2016.
91. Diclegis (doxylamine/pyridoxine) [prescribing information]. Bryn Mawr, PA: Duchesnay USA, Inc; April 2013.
92. Marinol (dronabinol) [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc; July 2006.
93. Hollister LE. Interactions of cannabis with other drugs in man. NIDA Res Monogr. 1986;68:110-116.3095648
94. Reisfield GM. Medical cannabis and chronic opioid therapy. J Pain Palliat Care Pharmacother. 2010;24(4):356-361.21133743
95. Droperidol injection [prescribing information]. Shirley, NY: American Regent Inc; January 2009.
96. Rohypnol [prescribing information]. Rio de Janeiro RJ, Brasil: Roche Chemicals and Pharmaceuticals SA; May 2014.
97. Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.
98. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.
99. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85-98.26333030
100. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study [published online June 10, 2015]. BMJ.2606321510.1136/bmj.h2698
101. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659.23423407
102. Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885.25299603
103. Zohydro ER (hydrocodone) [prescribing information]. San Diego, CA: Zogenix Inc; October 2013.
104. Vistaril (hydroxyzine) [prescribing information]. New York, NY: Pfizer Inc, April 2004.
105. Perez J, Holmes JF. Altered mental status and ataxia secondary to acute kava ingestion. J Emerg Med. 2005;28(1):49-51.15657005
106. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125(11):940-941.8967683
107. Capasso A, Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of kava kava and passiflora extracts combination. Phytomedicine. 2005;12(1-2):39-45.15693706
108. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777-1798.19719333
109. Sarris J. LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35.21073405
110. Dollery CT, Reid JL. Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects. Arzneimittelforschung. 1982;32(8a):984-987.6890374
111. BritLofex (lofexidine) [summary of product characteristics]. Berkshire, UK: Britannia Pharmaceuticals; August 2015.
112. Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC, January 2008.
113. Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira, Inc., November 2009.
114. Sikendar RI, us Samad B, Ali S, et al. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad, 2009, 21(2):132-135.20524490
115. Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482.17985581
116. Bilir A, Gulec S, Erkan A, et al. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523.17324976
117. McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for Caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231.20219345
118. Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369.17643282
119. Nozinan (methotrimeprazine) [prescribing information]. Laval, Quebec: Sanofi-Aventis Canada Inc.; May 2007.
120. Demser (metyrosine) [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; February 2010.
121. Minocin (minocycline) injection [prescribing information]. Parsippany, NJ: The Medicines Company; April 2015.
122. Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; December 2011.
123. Cesamet (nabilone) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals International; May 2006.
124. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.28972983
125. Norgesic (orphenadrine and paracetamol) [summary of product characteristics]. Chatswood, New South Wales, Australia: iNova Pharmaceuticals (Australia) Pty Limited; January 2014.
126. Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.
127. Roxicodone (oxycodone) [prescribing information]. Newport, KY: Xanodyne Pharmaceuticals Inc; March 2009.
128. Targiniq ER (oxycodone/naloxone) extended-release tablets [prescribing information]. Stamford CT: Purdue Pharma LP; July 2014.
129. Oxycontin (oxycodone) extended-release tablets [prescribing information]. Stamford CT: Purdue Pharma LP; August 2015.
130. Paraldehyde injection BP [product monograph]. Montreal, QC: Omega Laboratories Ltd., February 2011.
131. Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; July 2017.
132. Trivastal (piribedil) [summary of product characteristics]. Les Laboratories Servier; August 2013.
133. Mirapex (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; April 2012.
134. Requip XL (ropinirole) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2008.
135. Neupro (rotigotine) [prescribing information]. Smyrna, GA: UCB, Inc; April 2012.
136. Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2011.
137. Paxil (paroxetine) [prescribing information] .Research Triangle Park, NC: GlaxoSmithKline, March 2011.
138. Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, April 2011.
139. Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc, April 2011.
140. Celexa (citalopram) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc., January 2009.
141. Lexapro (escitalopram) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc., January 2009.
142. Luvox CR (fluvoxamine) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc., February 2009.
143. Viibryd (vilazodone) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc., April 2011.
144. Xyrem (sodium oxybate) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc., December 2012.
145. Belsomra (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; August 2014.
146. Nucynta (tapentadol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2013.
147. Sativex (tetrahydrocannabinol and cannabidiol oromucosal spray) [product monograph]. Toronto, ON: Bayer Inc; March 2012.
148. Thalidomid (thalidomide) [prescribing information]. Summit, NJ: Celgene Corporation, February 2013.
149. Panectyl (trimeprazine) [prescribing information]. Montreal, Quebec, Canada: ERFA Canada 2012 Inc; December 2015.
150. Intermezzo (zolpidem) [prescribing information]. Point Richmond, CA: Transcept Pharmaceuticals, Inc., November 2011.
151. Edluar (zolpidem) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc., October 2010.
152. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC, August 2010.
153. Rinlaxer (chlorphenesin carbamate) [prescribing information]. Toshima, Tokyo, Japan: Taisho Pharmaceutical Co., Ltd.; July 2009.
154. Vibrocil nasal drops, nasal gel, nasal spray, and microdoser (dimetindene maleate/phenylephrine base) [prescribing information]. Petach-Tikva, Israel: Promedico Ltd; November 1998.
155. Mysliwiec V, Martin JL, Ulmer CS, et al. The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Ann Intern Med. 2020 Feb 18.32066145
156. Burke H, Jiang S, Chatham P, Stern TA. Delirium after withdrawal from valerian root: A case report. Psychosomatics. 2020;61(6):787-790.32576405
157. Benke D, Barberis A, Kopp S, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009;56(1):174-181.18602406
158. Chen D, Klesmer J, Giovanniello A, Katz J. Mental status changes in an alcohol abuser taking valerian and gingko biloba. Am J Addict. 2002;11(1):75-77.11876586
159. Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32(12):1333-1336.15328251
160. Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol. 2003;23(3):260-268.12826988
161. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-426.15900287

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright © 2025 Wolters Kluwer Health